[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"covid-19-vaccines\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:covid-19-vaccines":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100649173","phase-4-a-study-to-learn-about-a-covid-19-vaccine-in-healthy-adults-18-through-64-years-of-age-100649173",false,"NCT07730450","A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age","A PHASE 4, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY-UNBLINDED STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF A BNT162B2 RNA-BASED, VARIANT-ADAPTED VACCINE CANDIDATE AGAINST SARS-COV-2 AND EVALUATE THE CIRCULATING SARS-COV-2 SPIKE PROTEIN LEVEL IN HEALTHY PARTICIPANTS 18 THROUGH 64 YEARS OF AGE","Key Inclusion Criteria\n\n\\- Healthy participants 18 through 64 years of age who do not have medical conditions that put them at a higher risk for severe COVID-19.\n\nKey Exclusion Criteria\n\n* Participants who tested positive for COVID-19 within 6 months (180 days) prior to Visit 1\n* Participants who have recently received a vaccine, or plan to receive a nonstudy COVID-19 or comparator vaccine during participation.\n\nThe complete list of inclusion and exclusion criteria are listed in the protocol.",true,"ALL","18 Years","64 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The purpose of this study is to learn about the safety and effects of an updated COVID-19 vaccine (called BNT162b2) in adults 18 to 64 years of age.\n\nThis study is seeking participants who:\n\n* are medically stable\n* have not had a recent COVID-19 infection\n* have not had a recent vaccination\n* do not have medical conditions that increase their risk of complications from COVID-19\n\nAll participants in this study will randomly receive 1 injection into their arm of either:\n\n* BNT162b2 vaccine which targets COVID-19 and is selected for the 2026-2027 COVID-19 season, or\n* Tdap vaccine which targets tetanus, diphtheria, and pertussis (whooping cough).\n\nThe study team and participants will not know which injection they receive. We will evaluate safety and SARS-CoV-2 spike protein levels in people receiving each of these vaccines.\n\nParticipants will be in the study for about 12 months.",[28],"COVID-19 Vaccines",[30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,28,50,51,52,53],"Pneumonia","Pneumonia, Viral","Respiratory Tract Infections","Infections","Virus Diseases","Coronavirus Infections","Coronaviridae Infections","Nidovirales Infections","RNA Virus Infections","Lung Diseases","Respiratory Tract Diseases","COVID-19","mRNA Vaccines","Nucleic Acid-Based Vaccines","Vaccines, Synthetic","Recombinant Proteins","Proteins","Amino Acids, Peptides, and Proteins","Vaccines","Biological Products","Viral Vaccines","Antigens","Biological Factors","BNT162 Vaccine","RECRUITING","2026-08-05",{"date":57,"type":58},"2026-08-07","ACTUAL",{"date":60,"type":58},"2026-07-23",{"date":62,"type":22},"2027-08-20",{"name":64,"class":65},"BioNTech SE","INDUSTRY",5]